Deuterated ruxolitinib

氘代芦可替尼

Report date: 2025/07/18 17:53:52
NME

Base Information

Drug NameDeuterated ruxolitinib
Drug Alias NameDeuterium modified ruxolitinibDeuruxolitinibD8-ruxolitinibD8-ruxolitinib phosphateDeuruxolitinib phosphate +[11] 
ClassificationSmall molecules > Heterocyclic drugsSmall molecules > Deuterated drugs
Mechanisms of ActionTyrosine-protein kinase JAK2 inhibitorsTyrosine-protein kinase JAK1 inhibitors
TargetsTyrosine-protein kinase JAK2Tyrosine-protein kinase JAK1
Therapy Area/IndicationsAlopecia AreataRenal InsufficiencyHepatic Insufficiency
Global Approved IndicationsAlopecia Areata
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/07/25
Country/TerritoryCanadaUnited StatesPoland +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesConcert Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesConcert Pharmaceuticals IncSun Pharmaceutical Industries IncSun Pharmaceutical Industries Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsAlopecia AreataRenal InsufficiencyHepatic Insufficiency
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A